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Tobacco smoking is a major risk factor for lung and upper-aerodi-
gestive-tract (UADT) cancers. One possible mechanism for the
associations may be through DNA damage pathways. DNA Ligase
I (LIG1) is a DNA repair gene involved in both the nucleotide exci-
sion repair (NER) and the base excision repair (BER) pathways.
We examined the association of 4 LIG1 polymorphisms with lung
and UADT cancers, and their potential interactions with smoking
in a population-based case-control study in Los Angeles County.
We performed genotyping using the SNPlex method from Applied
Biosystems. Logistic regression analyses of 551 lung cancer cases,
489 UADT cancer cases and 948 controls showed the expected
associations of tobacco smoking with lung and UADT cancers and
new associations between the LIG1 haplotypes and these cancers.
For lung cancer, when compared to the most common haplotype
(rs20581-rs20580-rs20579-rs439132 5 T-C-C-A), the adjusted
odds ratio (OR) is 1.2 (95% confidence limits (CL) 5 0.95, 1.5) for
the CACA haplotype, 1.4 (1.0, 1.9) for the CATA haplotype and
1.8 (1.1, 2.8) for the CCCG haplotype, after controlling for age,
gender, race/ethnicity, education and tobacco smoking. We
observed weaker associations between the LIG1 haplotypes and
UADT cancers. Our findings suggest the LIG1 haplotypes may
affect the risk of lung and UADT cancers.
' 2007 Wiley-Liss, Inc.
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Lung cancer patients have the poorest survival rates among can-
cer patients. The 5-year survival rate of lung cancer is only 11%
worldwide.1 It is also the most common cancer in the world and
the third most common cancer in the United States.1–3 In the
United States, lung cancer incidence ranks number three, while
lung cancer mortality ranks number one in 2006.3 Although sev-
eral risk factors for lung cancer such as tobacco smoking have
been identified,4 little is known about the role of genetic suscepti-
bility and its potential interactions with environmental factors.
Studies have examined associations between lung cancer and the
genetic polymorphisms of DNA repair genes; however, there are
no conclusive results on potential interactions with environmental
factors.
Upper-aerodigestive-tract (UADT) cancers of the oral cavity,
pharynx, larynx and esophagus accounts for 10% of new cases and
11% of cancer deaths worldwide in 2002.1 In the United States,
the estimated incidence and death rates are high in 2006.3 Oral/
pharyngeal, laryngeal and esophageal cancers show 5-year sur-
vival rates of 59, 64 and 16%, respectively, during 1995–2000.5
Tobacco and alcohol exposures have been well documented as
risk factors for head and neck squamous cell carcinomas.6–8 How-
ever, results of previous studies on the potential associations
between UADT cancers and the genetic polymorphisms of DNA
repair genes and their possible interactions with environmental
factors have been inconclusive.9,10
DNA is vulnerable to injury due to endogenous and/or exoge-
nous exposures11 such as exposure to carcinogens in tobacco
smoke. DNA repair systems play an important role in maintaining
the integrity of the genome. Deficiencies in this defense system
are thought to contribute to the development of cancer. Based on a
review of epidemiologic studies, Berwick and Vineis12 suggested
that reduced DNA repair capacity was associated with increased
risk of cancers, with odds ratios in the range of 1.4–75, with the
majority of values between 2 and 10. In addition, genetic variation
in DNA repair genes may influence DNA repair capacity; conse-
quently, DNA repair genetic polymorphisms may affect cancer
susceptibility.
DNA ligase I (LIG1) is a 102-kDa nuclear enzyme, which is
involved in joining Okazaki fragments during DNA replication
and in sealing single-strand breaks.13–15 It plays a role in both the
nucleotide excision repair (NER) and the long-patch base-excision
repair (BER) pathways.16,17 NER is an important DNA repair
pathway against tobacco-related carcinogenesis.18 A total of 31
SNPs for LIG1 were identified in SNP500 database (http://
snp500cancer.nci.nih.gov/snplist.cfm). The polymorphic sites
selected are shown in Figure 1. The T ! C synonymous SNP on
exon 25 (rs20581), the C ! A synonymous SNP on exon 7
(rs20580), C ! T synonymous SNP at 50 UTR on exon 2
(rs20579) and A ! G SNP on intron 1 (rs439132) do not result in
any alteration of amino acid19 and their functional variation is
unknown.20 They were selected because the LIG1 gene plays a
very important role in the BER pathway, and their rare allele fre-
quencies are greater or equal to 5%. The D’ between rs20581 and
rs20580 is 1.0; the D’ between rs20580 and rs20579 is 0.842; the
D’ between rs20581 and rs20579 is 1.0. These polymorphisms
might affect the transcription or translation of LIG1 protein for
DNA repair and, in turn, may influence DNA repair capacity. The
effect would thus take place after damage has occurred during car-
cinogenesis. These 4 SNPs may be associated with cancer risks
separately or jointly. Therefore, the haplotypes of LIG1 may play
a very important role.
We are aware of only one epidemiologic study that has exam-
ined the association between one of the LIG1 polymorphisms
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(rs20580) and lung cancer.20 That study, however, did not exam-
ine the associations of the other LIG1 SNPs, haplotypes and lung
cancer, and the joint effects of the LIG1 SNPs with tobacco smok-
ing. We know of no published studies that have explored the asso-
ciations between these LIG1 SNPs, haplotypes and lung and
UADT cancers. The objectives of the present study were to evalu-
ate the associations between the DNA repair genetic polymor-
phisms and haplotypes of DNA Ligase I (LIG1) and lung and
UADT cancer risks in the residential population of Los Angeles
County, and to investigate possible interactions between the LIG1
SNPs and haplotypes and environmental factors, particularly
tobacco smoking.
Material and methods
Study design and study participants
We used questionnaire data and buccal cell samples from a pop-
ulation-based case-control study, including 611 incident cases of
lung cancer, 601 incident cases of UADT cancer (403 oral/pharyn-
geal, 90 laryngeal and 108 esophageal) and 1,040 population con-
trols.21 Histologically confirmed newly diagnosed cancer cases
were obtained by the rapid ascertainment system of the Cancer
Surveillance Program for Los Angeles County, which is adminis-
tered by the Keck School of Medicine and Norris Comprehensive
Cancer Center at the University of Southern California. Over 95%
of cancer reports were histologically verified; the remainder was
verified by MRI, CT scan or other diagnostic methods. Controls
did not have a history of oral/pharyngeal, laryngeal, esophageal or
lung cancer and were identified using a formal algorithm that
enumerated households in the neighborhoods of the cases. Con-
trols were individually matched to cases by age (within 10-year
categories), gender and neighborhood.
All participants met the following criteria: (i) were residents of
Los Angeles County at the time of diagnosis for cases or at the
time of recruitment for controls, (ii) were 18–62 years of age dur-
ing the study period of 1999–2004 and (iii) spoke either English
or Spanish, or had translators available at the time of interview.
Additional details regarding recruitment and other exclusion crite-
ria have been described previously.21,22 Each case and control par-
ticipated in in-person interviews consisting of standardized ques-
tionnaires administered by specially trained interviewers. After
the interview, buccal swabs were collected for subsequent DNA
extraction.
Of the lung cancer and UADT cancer cases, respectively, 57
and 49% were interviewed within 3 months of diagnosis, 32 and
38% 3–6 months after diagnosis, and 11 and 12% more than 6
months after diagnosis. The response rates for those who were eli-
gible to be in the study were 68, 39, 49, 40 and 34% for controls,
lung cancer, oral/pharyngeal cancer, laryngeal cancer, and esopha-
geal cancer cases, respectively. Furthermore, the response rates
for those who completed interviews to provide the biospecimen
were 89, 89, 68, 88 and 90% for controls, lung cancer, oral/pha-
ryngeal cancer, laryngeal cancer and esophageal cancer cases,
respectively. The protocol was approved by the Institutional
Review Boards of the University of California, Los Angeles and
the University of Southern California. Informed consent was
obtained from every study subject.
Buccal cell samples
After participants were interviewed, interviewers collected
25–50 ml of buccal cells with ScopeTM mouthwash solution in
tubes. All buccal cell samples were transported as soon as possible
to the School of Public Health, University of California, Los
Angeles where samples were stored at 4C in the molecular epide-
miology laboratory refrigerator. The buccal cell samples were cen-
trifuged to separate the buccal cells and mouthwash solution. High
molecular weight DNA was isolated by an altered phenol-chloro-
form method.23 DNA purity and concentration were determined
by a spectrophotometric measurement of absorbance at 260/280
nm.
Genotyping assays
Genotypes of LIG1 were determined using the Applied Biosys-
tems SNPlexTM assay.24 This method assays SNP genotypes in 48
SNP PCR multiplexes using an oligonucleotide ligation process.
Each SNP allele was ligated to an allele-specific oligonucleotide,
then hybridized with a ZipchuteTM probe with a mobility modifier
and a fluorescent label, allowing the probe to be separated and
detected by capillary electrophoresis. Detection was performed on
an Applied Biosystems 3730 DNA Analyzer, and data interpreta-
tion was performed with the Applied Biosystems Genemapper
software v4.0, which uses a clustering algorithm with stringent
proprietary quality checks to call genotypes. SNPlex genotyping
was performed by the UCLA Genotyping Core. All automatic
calls by the software were evaluated by Core technicians. Any
SNPs with less than 90% of the sample auto-called by the software
were either rescored manually or discarded if clustering confi-
dence was low. Samples were run with 2 positive controls of
CEPH individual 1347-2 and 2 ‘‘no template", negative controls
per 96-well plate. Any run in which the positive controls failed to
cluster was discarded. Only genotypes with a Genemapper Quality
Score of greater than 95% were passed. On the DNA samples in
this study, the call rate was 96%, the reproducibility rate was
97.8% and the concordance rate was 99.8%. Reproducibility was
determined by comparing blinded replicates on plates and by
rerunning entire plates. The reproducibility reported was calcu-
lated over 10,000 duplicate genotypes (3% of the entire sample),
including not only blinded replicates on the same plate or the
FIGURE 1 – The selected polymorphic sites of LIG1. [Color figure can
be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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same run, but also plates repeated on the entire assay, including all
preprocessing steps, as much as 6 months apart. Concordance was
determined by Taqman assay on ABI 7900. For concordance tests,
we chose one SNP with high call rates, one average SNP and one
SNP with low call rates (60%). These SNPs were genotyped on
one 96-well plate with high-quality DNA and high call rates and
one plate with low-quality DNA and low call rates. The concord-
ance rate of genotypes called successfully on both SNPlex and
Taqman was not affected by SNP quality or DNA quality,
although the samples with low call rates on SNPlex also had low
call rates on Taqman. All genotypes were checked for Hardy-
Weinberg equilibrium and divergence from published allele fre-
quencies. Checks were performed across the entire sample and on
individual genotyping runs to identify any possibly bad runs. Any
markers, sample sets or genotyping runs that gave suspect results
on HWE or on any of our other quality control validation tests
were manually rescored.
Statistical analyses
Data analyses were performed with SAS 9 software. All P-val-
ues are 2-sided. To increase the precision and power over standard
matched analyses, we compared each cancer group (lung and
UDAT) with all controls using unconditional logistic regression,
including terms for the matching factors, age and sex, which
allowed us to include cases with no matched controls.25 Odds-ratio
estimates (ORs) and 95% confidence limits (CLs) were computed
with and without adjustment for potential confounders including
age, gender, race/ethnicity (white, Hispanic, African American,
Asian/Pacific Islander and other), educational level, alcohol drink-
ing and tobacco smoking. To minimize age confounding and to
account for age matching, age was controlled in fine categories
(<35, 35–36, 37–38, 39–40, 41–42, 43–44, 45–46, 47–48, 49–50,
51–52, 53–54, 55–56, 57–58 and 59–62). Controls who were more
than 3 years younger than the youngest case or 3 years older than
the oldest case were excluded from the analysis. Educational level
(years of schooling) and tobacco smoking (pack-years) were con-
trolled as continuous variables.
We assessed the results for the LIG1 polymorphisms by treat-
ing participants with the homozygote wild-type genotype as the
referent. We performed the Pearson (v2) test to evaluate Hardy-
Weinberg equilibrium among the controls. The haplotypes were
reconstructed from our population genotype data, using PHASE
v2.26,27 We treated the most frequent haplotype as the referent.
The impact of tobacco smoking on the association of the LIG1
genotypes and haplotypes was also investigated by stratified
analysis.
Results
Lung cancer cases ranged from 32 to 59 years of age, while
oral/pharyngeal, laryngeal and esophageal cancer cases ranged
from 17 to 59 years of age. Based on the age restriction mentioned
previously, eleven controls were excluded from the lung-cancer
analyses, and one control was excluded from the UADT-cancer
analyses.
Among the lung cancer cases, there were 95 squamous cell
carcinoma, 297 adenocarcinoma, 115 large cell lung cancer and
75 small cell lung cancer; among the UADT cancer cases, there
were 497 squamous cell carcinomas. Table I shows the compar-
isons between interviewed cases and controls with and without
DNA specimens. There were appreciable differences in race/eth-
nicity between those with and without DNA specimens among
both UADT cancer cases and population controls; African
Americans were less likely to provide DNA specimens. Women
were less likely than men to provide DNA specimens in all
case and control groups, and college-educated cases of lung
cancer were less likely to provide DNA specimens than those
with less education. The association of DNA sampling with
these covariates implies that adjustment for them would be
needed.
Table II shows the associations between tobacco smoking and
lung and UADT cancer risk. Tobacco smoking (> 40 pack-years
vs. 0 pack-years) was strongly associated with increased cancer
risk with odds ratios of 22 (95% CL 5 15, 33) for lung cancer and
4.3 (95% CL 5 2.9, 6.4) for UADT cancers after adjusting for
age, gender, ethnicity and education (plus alcohol drinking for
UADT cancers only). The age at initiation of smoking (16-years
old and >16-years old vs. never started) was also strongly associ-
ated with lung cancer (OR 5 5.7, 95% CL 5 4.3, 7.6 for 16-
TABLE II – THE ASSOCIATIONS BETWEEN TOBACCO SMOKING, LUNG CANCER, AND UADT CANCER
Lung cancer UADT cancers
Tobacco smoking Cases N Controls N Adjusted OR1 (95% CL) Cases N Controls N Adjusted OR2 (95% CL)
Smoking status
Never 110 484 1.0 182 491 1.0
Ever 501 545 4.1 (3.2, 5.3) 419 548 1.5 (1.2, 1.9)
Former 360 361 4.4 (3.4, 5.7) 314 362 1.8 (1.4, 2.3)
Current 141 184 3.7 (2.7, 5.0) 105 186 0.93 (0.67, 1.3)
ptrend < 0.0001 ptrend 5 0.45
Pack-years
0 110 484 1.0 182 491 1.0
>0–20 102 350 1.4 (0.99, 1.9) 147 353 0.99 (0.76, 1.3)
>20–40 202 136 8.3 (6.0, 12) 146 136 2.3 (1.7, 3.2)
>40 197 58 22 (15, 33) 126 58 4.3 (2.9, 6.4)
ptrend < 0.0001 ptrend < 0.0001
Age started smoking
Never 110 484 1.0 182 491 1.0
>16 222 317 3.1 (2.3, 4.1) 182 319 1.3 (0.96, 1.6)
16 279 227 5.7 (4.3, 7.6) 237 228 1.9 (1.5, 2.5)
ptrend < 0.0001 ptrend 5 0.22
Years since quitting smoking
0 141 184 1.0 105 186 1.0
1–4 241 55 5.4 (3.7, 7.9) 201 56 7.7 (5.1, 12)
>4–12 64 66 1.1 (0.74, 1.7) 37 66 1.2 (0.73, 2.0)
>12 55 240 0.27 (0.19, 0.40) 76 240 0.71 (0.48, 1.0)
ptrend < 0.0001 ptrend < 0.0001
1Adjusted for age, gender, ethnicity and education.–2Adjusted for age, gender, ethnicity, education and alcohol-years (alcohol drinks/day 3
years).
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TABLE III – THE ASSOCIATIONS BETWEEN THE FOUR LIG1 POLYMORPHISMS AND LUNG CANCER
Genotype of LIG1 Cases Controls Crude OR Adj. OR1
Rs20581 (Exon 25)
T/T 78 142 1.0 1.0
C/T 148 346 0.78 (0.56, 1.1) 0.92 (0.62, 1.4)
C/C 86 155 1.0 (0.69, 1.5) 1.2 (0.74, 1.8)
Stratified by smoking status in pack-years2
0
T/T 12 62 1.0 1.0
C/T 23 164 0.73 (0.34, 1.5) 0.70 (0.32, 1.5)
C/C 21 71 1.5 (0.70, 3.4) 1.1 (0.49, 2.7)
>0–20
T/T 7 45 1.0 1.0
C/T 31 116 1.7 (0.71, 4.2) 1.6 (0.62, 3.9)
C/C 15 60 1.6 (0.61, 4.3) 1.5 (0.54, 4.1)
>20
T/T 59 35 1.0 1.0
C/T 94 66 0.85(0.50, 1.4) 0.81 (0.47, 1.4)
C/C 50 23 1.3 (0.68, 2.5) 1.1 (0.58, 2.2)
Rs20580 (Exon 7)
C/C 110 202 1.0 1.0
A/C 211 398 0.97 (0.73, 1.3) 1.0 (0.72, 1.4)
A/A 121 179 1.2 (0.90, 1.7) 1.2 (0.85, 1.8)
Stratified by smoking status in pack-years2
0
C/C 20 97 1.0 1.0
A/C 36 183 0.95 (0.52, 1.7) 0.83 (0.44, 1.6)
A/A 24 80 1.5 (0.75, 2.8) 1.1 (0.55, 2.3)
>0–20
C/C 14 62 1.0 1.0
A/C 34 139 1.1 (0.54, 2.2) 1.1 (0.52, 2.2)
A/A 21 66 1.4 (0.66, 3.0) 1.5 (0.67, 3.2)
>20
C/C 76 43 1.0 1.0
A/C 141 76 1.1 (0.66, 1.7) 1.0 (0.64, 1.7)
A/A 76 33 1.3 (0.75, 2.3) 1.2 (0.71, 2.2)
Rs20579 (Exon 2)
C/C 294 586 1.0 1.0
C/T 118 187 1.3 (0.96, 1.6) 1.3 (0.97, 1.8)
T/T 11 7 3.1 (1.2, 8.2) 2.1 (0.74, 5.9)
Stratified by smoking status in pack-years2
0
C/C 58 276 1.0 1.0
C/T 15 88 0.81 (0.44, 1.5) 0.84 (0.44, 1.6)
T/T 1 0 – –
>0–20
C/C 40 192 1.0 1.0
C/T 23 66 1.7 (0.93, 3.0) 1.7 (0.92, 3.1)
T/T 4 4 4.8 (1.2, 20) 3.8 (0.86, 17)
>20
C/C 196 118 1.0 1.0
C/T 80 33 1.5 (0.92, 2.3) 1.5 (0.91, 2.4)
T/T 6 3 1.2 (0.30, 4.9) 1.2 (0.30, 5.2)
Rs439132 (Intron 1)
A/A 326 585 1.0 1.0
A/G 39 54 1.3 (0.84, 2.0) 1.3 (0.81, 2.3)
G/G 6 2 5.4 (1.1, 27) 5.3 (0.92, 30)
Stratified by smoking status in pack-years2
0
A/A 51 284 1.0 1.0
A/G 10 23 2.4 (1.1, 5.4) 1.7 (0.74, 4.1)
G/G 0 1 – –
>0–20
A/A 47 184 1.0 1.0
A/G 5 24 0.82 (0.30, 2.3) 0.78 (0.27, 2.2)
G/G 2 1 7.8 (0.70, 88) 5.2 (0.44, 60)
>20
A/A 228 117 1.0 1.0
A/G 24 7 1.8 (0.74, 4.2) 1.5 (0.61, 3.8)
G/G 4 0 – –
1Adjusted for gender, age, education, ethnicity and tobacco smoking (pack-years).–2Adjusted for gen-
der, age, education and ethnicity.
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TABLE IV – THE ASSOCIATIONS BETWEEN THE FOUR LIG1 POLYMORPHISMS AND UADT CANCER
Genotype of LIG1 Cases Controls Crude OR Adj. OR1
Rs20581 (Exon 25)
T/T 61 143 1.0 1.0
C/T 164 350 1.1 (0.77, 1.6) 1.2 (0.85, 1.8)
C/C 94 157 1.4 (0.95, 2.1) 1.5 (1.0, 2.3)
Stratified by smoking status in pack-years2
0
T/T 23 62 1.0 1.0
C/T 58 167 0.94 (0.53, 1.6) 0.89 (0.50, 1.6)
C/C 25 72 0.94 (0.48, 1.8) 0.83 (0.42, 1.6)
>0–20
T/T 9 46 1.0 1.0
C/T 47 117 2.1(0.93, 4.5) 1.7 (0.74, 4.8)
C/C 28 61 2.3 (1.0, 5.5) 2.3 (0.95, 5.4)
>20
T/T 29 35 1.0 1.0
C/T 59 66 1.1 (0.59, 2.0) 1.2 (0.62, 2.2)
C/C 41 23 2.2 (1.1, 4.4) 2.2 (1.0, 4.7)
Rs20580 (Exon 7)
C/C 91 203 1.0 1.0
A/C 197 403 1.1 (0.81, 1.5) 1.1 (0.83, 1.6)
A/A 99 180 1.2 (0.87, 1.7) 1.2 (0.83, 1.7)
Stratified by smoking status in pack-years2
0
C/C 34 98 1.0 1.0
A/C 64 187 0.99 (0.61, 1.6) 0.98 (0.60, 1.6)
A/A 24 80 0.86 (0.47, 1.6) 0.86 (0.47, 1.6)
>0–20
C/C 16 67 1.0 1.0
A/C 50 140 1.4 (0.73, 2.6) 1.3 (0.68, 2.5)
A/A 26 62 1.5 (0.74, 3.1) 1.5 (0.74, 3.2)
>20
C/C 41 43 1.0 1.0
A/C 83 76 1.1 (0.68, 1.9) 1.3 (0.73, 2.3)
A/A 49 33 1.6 (0.84, 2.9) 1.6 (0.84, 3.1)
Rs20579 (Exon 2)
C/C 264 592 1.0 1.0
C/T 108 188 1.3 (0.98, 1.7) 1.3 (1.0, 1.8)
T/T 8 7 2.6 (0.92, 7.1) 2.0 (0.69, 5.8)
Stratified by smoking status in pack-years2
0
C/C 80 281 1.0 1.0
C/T 35 88 1.4 (0.88, 2.2) 1.5 (0.91, 2.3)
T/T 3 0 – –
>0–20
C/C 67 193 1.0 1.0
C/T 24 67 1.0 (0.60, 1.8) 1.1 (0.61, 1.9)
T/T 2 4 1.4 (0.26, 8.0) 1.2 (0.21, 6.9)
>20
C/C 117 118 1.0 1.0
C/T 49 33 1.5 (0.90, 2.5) 1.5 (0.88, 2.6)
T/T 3 3 1.0 (0.20, 5.1) 0.95 (0.18, 5.0)
Rs439132 (Intron 1)
A/A 297 590 1.0 1.0
A/G 23 54 0.85 (0.51, 1.4) 0.78 (0.45, 1.4)
G/G 8 2 7.9 (1.7, 38) 5.9 (1.1, 31)
Stratified by smoking status in pack-years2
0
A/A 100 288 1.0 1.0
A/G 5 23 0.63 (0.23, 1.7) 0.58 (0.21, 1.6)
G/G 1 1 2.9 (0.18, 46) 2.7 (0.16, 45)
>0–20
A/A 70 185 1.0 1.0
A/G 3 24 0.33 (0.096, 1.1) 0.32 (0.092, 1.1)
G/G 1 1 2.6 (0.16, 43) 3.3 (0.18, 60)
>20
A/A 127 117 1.0 1.0
A/G 15 7 2.0 (0.78, 5.0) 2.0 (0.74, 5.7)
G/G 6 0 – –
1Adjusted for gender, age, education, ethnicity and tobacco smoking (pack-years).–2Adjusted for
gender, age, education and ethnicity.
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years old; OR 5 3.1, 95% CL 5 2.3, 4.1 for >16-years old) and
UADT cancers (OR 5 1.9, 95% CL5 1.5, 2.5 for 16-years old;
OR 5 1.3, 95% CL 5 0.96, 1.6 for >16-years old) (Table II).
We did not detect departure from Hardy-Weinberg equilibrium
for the genotyping frequencies among the controls. Adjusting for
age, sex, race/ethnicity, education and pack-years of tobacco
smoking, there was little or no association between the LIG1 poly-
morphisms on exon 25 and exon 7 and lung-cancer incidence (Ta-
ble III). Weak-to-moderate associations were observed between
the LIG1 SNPs on exon 2 and intron 1 and lung-cancer incidence,
but these associations were not estimated precisely. The adjusted
OR was 1.3 (95% CL 5 0.97, 1.8) for the CT vs. CC genotype and
2.1 (95% CL 5 0.74, 5.9) for the TT vs. CC genotype on exon 2
and 5.3 (95% CL 5 0.92, 30) for the GG vs. AA genotype on
intron 1. For the associations between the SNPs on exon 25, on
exon 2 and on intron 1 and UADT cancer incidence (Table IV),
the adjusted OR was 1.5 (95% CL 5 1.0, 2.3) for the CC vs. TT
genotype on exon 25, 1.3 (95% CL 5 1.0, 1.8) for the CT vs. CC
genotype and 2.0 (95% CL 5 0.69, 5.8) for the TT vs. CC geno-
type on exon 2, and 5.9 (95% CL5 1.1, 31) for the GG vs. AA
genotype on intron 1.
When stratifying on pack-years of smoking, we observed higher
OR estimates among ever smokers (both  20 and >20 pack-
years) than among never smokers for the associations of the SNPs
on exons 25 and 7 with UADT cancers (Table IV), but this pattern
was not observed in the other analyses (Tables III and IV). Fur-
thermore, likelihood-ratio tests for the interactions on the multipli-
cative scale between the SNPs and pack-years of smoking yielded
p values of 0.46 for exon 25 (rs20581), 0.99 for exon 7 (rs20580),
0.58 for exon 2 (rs20579) and 0.84 for intron 1 (rs439132) for
lung cancer, and 0.31 for exon 25, 0.75 for exon 7, 0.82 for exon 2
and 0.29 for intron 1 for UADT cancers.
The haplotypes of the 4 LIG1 polymorphisms were recon-
structed, and the frequencies of the more common haplotypes (5%
or higher) are shown in Tables V and VI. For lung cancer, when
compared to the most common haplotype (rs20581-rs20580-
rs20579-rs439132 5 T-C-C-A), the adjusted OR was 1.2 (95%
CL 5 0.95, 1.5) for the CACA haplotype, 1.4 (1.0, 1.9) for the
CATA haplotype and 1.8 (1.1, 2.8) for the CCCG haplotype. In
addition, the association with the CATA haplotype was more evi-
dent among moderate smokers (>0–20 pack-years). The test for
interaction between haplotypes and pack-years yielded a p value
of 0.99.
For UADT cancers, when compared to the most common haplo-
type (rs20581-rs20580-rs20579-rs439132 5 T-C-C-A), the adjusted
OR was 1.1 (95% CL 5 0.87, 1.3) for the CACA haplotype, 1.2
(0.92, 1.7) for the CATA haplotype and 1.5 (0.96, 2.3) for the
CCCG haplotype. In addition, the associations with the CACA
haplotype and the CCCG haplotype were more evident among
heavy smokers (>20 pack-years) with the adjusted ORs of 1.4
(0.99, 2.1) and 6.3 (2.4, 17), respectively (Table VI). The test for
interaction yielded a p value of 0.08.
Discussion
DNA ligase I (LIG1), located on chromosome 19,13 is a 102-
kDa nuclear enzyme that appears to be involved in joining Oka-
zaki fragments during DNA replication and in sealing single-
strand breaks in the base excision repair pathway.13–15 Bentley
et al. suggested that LIG1 null cells have normal DNA repair
capacity, but also have increased genome instability,28 possibly
affecting cancer susceptibility. It is important to identify the func-
tional significance of the LIG1 polymorphism to interpret its
potential effects on cancer development in the population.29,30
LIG1 was thought to be essential for cell viability; however, Bent-
ley et al. observed that cells lacking DNA ligase 1 are viable.28
Bentley et al. hypothesized that the function of LIG1 may be com-
pensated by another ligase gene.28 This hypothesis warrants fur-
ther investigation.
TABLE V – THE ASSOCIATIONS OF THE 4 LIG1 HAPLOTYPES AND LUNG CANCER
TCCA CACA CATA CCCG CCCA CCTA TACA All others
Overall, n (case/control) 346/695 325/582 112/169 51/65 11/25 18/28 3/8 10/6
1.0 1.2 1.4 1.8 0.81 1.6 1.3 3.2
Adj. OR1 (0.95, 1.5) (1.0, 1.9) (1.1, 2.8) (0.35, 1.9) (0.78, 3.1) (0.31, 5.9) (0.99, 11)
Stratified by smoking status in pack-years
0 55/322 68/272 15/71 13/30 1/15 1/15 0/5 1/2
1.0 1.2 0.98 1.6 0.31 0.46 – 3.1
Adj. OR2 (0.83, 1.9) (0.50, 1.9) (0.77, 3.5) (0.039, 2.5) (0.058, 3.7) (0.26, 38)
>0–20 44/222 49/202 24/65 10/29 1/7 6/7 2/3 0/3
1.0 1.3 1.8 1.7 0.55 4.5 3.8 –
Adj. OR2 (0.79, 2.0) (1.0, 3.3) (0.74, 3.8) (0.064, 4.8) (1.4, 15) (0.59, 25)
>20 247/151 208/108 73/33 28/6 9/3 11/6 1/0 9/1
1.0 1.2 1.3 2.2 1.9 1.2 – 5.7
Adj. OR2 (0.85, 1.6) (0.81, 2.1) (0.85, 5.6) (0.49, 7.1) (0.44, 3.5) (0.70, 46)
1Adjusted for gender, age, education, ethnicity and tobacco smoking (pack-years).–2Adjusted for gender, age, education and ethnicity.
TABLE VI – THE ASSOCIATIONS OF THE 4 LIG1 HAPLOTYPES AND UADT CANCERS
TCCA CACA CATA CCCG CCCA CCTA TACA All others
Overall, n (case/control) 309/698 284/588 97/172 48/67 9/26 17/28 7/8 9/5
Adj. OR1 1.0 1.1 1.2 1.5 1.1 1.4 2.5 3.3
(0.87, 1.3) (0.92, 1.7) (0.96, 2.3) (0.49, 2.4) (0.73, 2.8) (0.86, 7.2) (0.97, 11)
Stratified by smoking status in pack-years
0 108/326 75/275 33/72 10/31 3/16 6/15 2/5 3/2
Adj. OR2 1.0 0.77 1.4 0.86 0.65 1.4 1.3 5.2
(0.55, 1.1) (0.86, 2.2) (0.40, 1.9) (0.18, 2.3) (0.51, 3.7) (0.25, 6.9) (0.85, 32)
>0–20 70/222 74/204 25/67 8/30 5/7 1/7 3/3 0/2
Adj. OR2 1.0 1.2 1.1 0.73 2.4 0.52 3.2 –
(0.80, 1.7) (0.65, 2.0) (0.31, 1.7) (0.67, 8.3) (0.062, 4.4) (0.61, 17)
>20 131/150 135/109 39/33 30/6 1/3 10/6 2/0 6/1
Adj. OR2 1.0 1.4 1.3 6.3 0.40 2.0 – 5.3
(0.99, 2.1) (0.74, 2.3) (2.4, 17) (0.039, 4.1) (0.67, 6.1) (0.58, 48)
1Adjusted for gender, age, education, ethnicity and tobacco smoking (pack-years).–2Adjusted for gender, age, education and ethnicity.
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DNA repair plays an essential role by protecting cells’ chromo-
somes from environmental exposure, such as tobacco smoke.31
Among the different repair pathways, base excision repair
removes small lesions, DNA single strand breaks and nonbulky
adducts.31 An observed association between increased risk of
UADT cancer and higher levels of BPDE-induced DNA adducts
in peripheral lymphocytes may reflect a combination of carcino-
gen metabolism and DNA repair.32 An increasing number of pub-
lications imply the association between reduced DNA repair
capacity and altered cancer risk and the association between DNA
repair genetic variations and DNA repair function and the conse-
quently modified cancer risk.33–36
Only weak associations with the haplotypes of LIG1 for lung
cancer and associations with the genotypes of LIG1 polymor-
phisms and the haplotypes for UADT cancer were observed in this
study. For a few of the associations, the data showed more pro-
nounced patterns among moderate and/or heavy smokers, consist-
ent with our expectation to see stronger genotype associations
among moderate/heavy smokers. In addition, interactions between
smoking and the polymorphisms on the development of the
above-mentioned cancers were implied, based on the stratified
analyses. However, we had limited power to detect the extent of
the potential interactions.
A previous study on the LIG1 polymorphism on exon 7
(rs20580) and lung cancer detected no association between the
LIG1 polymorphism and the risk of lung cancer in a case-control
study that included non-Hispanic whites (OR 5 1.0, 95% CL 0.8,
1.5 for the AC vs. CC genotype; OR 5 0.93, 95% CL 0.6, 1.4 for
the AA vs. CC genotype) after adjusting for age, sex, smoking,
alcohol use and family history of cancer.20 In our study, we also
investigated ethnic groups other than Caucasians. However, we
did not have enough subjects to detect interactions with ethnicity,
upon examining the combined associations of these 4 LIG1 poly-
morphisms and tobacco smoking with lung and UADT cancers.
Nonetheless, when we considered all 4 of the SNPs together as
haplotypes, we observed associations between the LIG1 haplotypes
and the cancer risks. Our findings showed the possibility that these 4
LIG1 polymorphisms and haplotypes may play a role in the suscepti-
bility to the cancers of interest. Tobacco smoking results in the for-
mation of adducts on DNA.37 The main pathway for repairing this
type of DNA damage is NER.30,38 Since LIG1 is involved in the
NER and BER pathways,30 there is potential for interaction between
this SNP and tobacco smoking. The associations of the LIG1 poly-
morphisms and haplotypes with lung and head and neck cancers
among moderate/heavy smokers may suggest carcinogenesis mecha-
nisms involving exposure to tobacco smoke.
Another possible explanation for the observed association is
that the examined SNPs could be in linkage disequilibrium with
other functional SNPs that were not genotyped. Functional studies
on the LIG1 gene are warranted to test these hypotheses. Given
the limited precision for interaction assessment in single studies,
further studies of these effects are needed and study samples will
have to be carefully pooled to obtain an accurate picture of gene-
environment and gene–gene interactions. Furthermore, although
diplotypes represent the chromosome pairs for a particular individ-
ual, and thus are more informative to assessing individual risk, we
do not have enough power to assess diplotypes due to the limited
sample size. Studies with larger sample sizes are warranted for
further investigation on diplotypes.
A major strength of this study was that the study design was
population-based. The controls were selected from the same popu-
lation that gave rise to the cases based on a neighborhood-match-
ing algorithm; therefore, it reduced an important potential source
of selection bias.
Despite its strengths, this study also has a number of limitations.
There might be possible selection bias introduced by nonparticipa-
tion of eligible persons, due to premature death, refusal or inability
to contact. Lung cancer cases with poor prognoses may result in a
rapid progression to an advanced stage, precluding interviews and
participation in the study and resulting in possible selection bias.
Nonetheless, the active surveillance procedure, which was used to
identify cases shortly after diagnosis, reduces this problem. Recall
bias may occur due to the nature in which information is collected in
a case-control study. Compared to controls, cases might differen-
tially recall exposures of tobacco smoking or alcohol consumption
because of their cancer diagnosis. Reporting bias might occur if cer-
tain exposures are under or overreported, especially if behaviors or
habits, such as tobacco smoking, carry a social stigma in the popula-
tion. On the other hand, we expect minimal misclassification of the
DNA repair genetic polymorphisms. Standard laboratory protocols
were used to genotype the markers, while the laboratory personnel
were blinded to the case-control status of the samples.
Additionally, our sample size, although modest, provided lim-
ited power to detect associations in subgroups, especially for the
rare variants. We also assessed the false positive reporting proba-
bilities (FPRPs) according to Wacholder et al.39 With a prior of
25% for UADT cancer, the FPRP is 27% for Rs20581 (Exon 25)
C/C vs. T/T; 24% for Rs20581 (Exon 25) C/C vs. T/T among
heavy smokers; and 18% for Rs439132 (Intron 1) G/G vs. A/A.
Thus, the probability of false positives among the reported associ-
ations is high.
In summary, we observed weak-to-moderate associations of the
LIG1 polymorphisms (on exon 2 and on intron 1) with lung cancer
and of the LIG1 polymorphisms (on exon 25, on exon 2 and on intron
1) with UADT cancers. Despite limitations of possible bias and
imprecise estimation for rare genotypes and haplotypes, our findings
suggest that LIG1 polymorphisms and haplotypes may affect the risk
of lung and UADT cancers. Although observing such effects may
help us better understand the mechanisms through which smoking
increases cancer risk, further research is needed to examine gene-
smoking and gene–gene interactions in large populations.
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